Comparative Pharmacology
Head-to-head clinical analysis: ARSENIC TRIOXIDE versus SCEMBLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARSENIC TRIOXIDE versus SCEMBLIX.
ARSENIC TRIOXIDE vs SCEMBLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Arsenic trioxide induces apoptosis in acute promyelocytic leukemia (APL) cells through degradation of PML-RARα fusion protein and modulation of mitochondrial pathways.
Selective inhibitor of BCR-ABL1 tyrosine kinase, targeting the myristoyl pocket (STAMP) to induce inactive conformation of BCR-ABL1, including T315I mutant.
0.15 mg/kg IV daily until remission, then 0.15 mg/kg IV 5 days per week for 5 weeks (consolidation); dose based on actual body weight.
200 mg orally once daily with a meal.
None Documented
None Documented
Terminal elimination half-life of inorganic arsenic is approximately 10–14 hours for the trivalent form, but for total arsenic (including methylated metabolites) the half-life ranges from 10 to 32 hours. Clinical context: due to extensive tissue distribution and metabolic conversion, the effective half-life for pharmacodynamic effect is prolonged, with repeated dosing leading to accumulation. The terminal half-life is biphasic: an initial distribution phase of about 2 hours and a terminal phase of 10–14 hours.
Clinical Note
moderateArsenic trioxide + Digoxin
"Arsenic trioxide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateArsenic trioxide + Digitoxin
"Arsenic trioxide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateArsenic trioxide + Deslanoside
"Arsenic trioxide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateArsenic trioxide + Acetyldigitoxin
Terminal elimination half-life approximately 21–23 hours (range 10–35 h). Supports once-daily dosing.
Primarily renal excretion; after intravenous administration, approximately 15% of the dose is excreted unchanged in urine over 24 hours. Biliary/fecal excretion accounts for less than 5% as unchanged drug; the majority is eliminated as methylated metabolites (monomethylarsonic acid and dimethylarsinic acid) via urine, with total urinary excretion of arsenic species reaching 60-85% of the dose within 14 days.
Primarily fecal (77%) with minor renal excretion (11%). Biliary excretion contributes to fecal elimination; <1% excreted unchanged in urine.
Category C
Category C
Antineoplastic
Tyrosine Kinase Inhibitor, Antineoplastic
"Arsenic trioxide may decrease the cardiotoxic activities of Acetyldigitoxin."